The retailer’s common stock will continue to be listed and traded on the NYSE during the 'cure periods,' subject to the company’s compliance with other continued listing requirements.
Xolair, which contains omalizumab, is indicated for diseases such as severe persistent allergic asthma, chronic rhinosinusitis with nasal polyps and chronic spontaneous urticaria.
